Bausch Health raises 2026 guidance after second-quarter revenue climbs 13%
The company reported $2.85 billion in second-quarter revenue and lifted its full-year outlook, citing growth at the Salix and Bausch + Lomb segments.
Bausch Health Companies reported second-quarter 2026 results on July 29, 2026, and raised its full-year guidance. Total consolidated revenue reached $2.85 billion for the second quarter of 2026, compared with $2.53 billion in the second quarter of 2025, an increase of $322 million, or 13%.1 Excluding foreign exchange and deal-related effects, revenue increased 11% on an organic basis compared with the second quarter of 2025.1
Segment performance varied. The Salix unit posted reported revenues of $758 million for the second quarter of 2026, compared with $627 million for the second quarter of 2025, an increase of $131 million, or 21%1, with Xifaxan as the primary contributor to growth, with 26% revenue growth in the second quarter of 2026.1 The Bausch + Lomb segment reported revenues of $1.39 billion for the second quarter of 2026, compared with $1.28 billion for the second quarter of 2025, an increase of $116 million, or 9%1.
On guidance, the company said Bausch Health, excluding Bausch + Lomb, is raising its full-year revenue, adjusted EBITDA, and adjusted cash flows from operations guidance, which includes the currently estimated impact of applicable tariffs for the calendar year as of the date of the release.1 As of July 29, 2026, consolidated guidance calls for revenues of $10.790 to $11.040 billion companywide, $5.350 to $5.500 billion excluding Bausch + Lomb, and $5.440 to $5.540 billion for Bausch + Lomb, with total revenue growth versus the prior year projected at 4% to 6%.1
On the balance sheet, the company reported consolidated cash and cash equivalents of $1,825 million as of June 30, 2026, up from $1,309 million as of December 31, 2025.1 Management said the company entered the second half of 2026 with strong financial momentum across multiple segments and, following major refinancing completed over the prior twelve months, materially improved its debt maturity profile.1 The company also said it remains committed to evaluating all options for unlocking shareholder value, including maximizing the value of its Bausch Health and Bausch + Lomb assets.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.